Valence ロゴ
人気
ログイン
Loading data for MSB — first visit, this takes a few seconds.

ウォッチリストに追加

Mesabi Trust

NYSE: MSB · リアルタイム株価 · USD
23.19
+0.06 (0.26%)
終値時点： Aug 18, 2026, 3:58 PM

Mesabi Trust (MSB) Stock Price, Analysis & Data

0.26%
買気配20.51
時価総額304.25M
売上高（TTM）15.04M
純利益（TTM）11.33M
ベータ0.33
EPS（TTM）0.86
PER（TTM）26.97
予想PER-1.17
PBR（TTM）16.59
PSR（TTM）20.24
Earnings Daten/a
売気配28
出来高23,288
平均出来高（20日）45,867
始値23.13
前日終値23.13
当日レンジ22.86 - 23.36
52週レンジ21.60 - 42.38
アナリストn/a
目標株価n/a
配当$0.89 (3.84%)
権利落ち日2026年7月30日

MSBについて

Mesabi Trust, a royalty trust, engages in iron ore mining business in the United States. Mesabi Trust was incorporated in 1961 and is based in New York, New York....

[続きを読む]
業種 Steel
セクター Basic Materials
IPO日 Feb 21, 1973
従業員数 n/a
上場取引所 NYSE
ティッカー MSB
ウェブサイト https://mesabi-trust.com
企業情報の全文

業績

2026年のMesabi Trustの売上高は16.57Mで、前年の25.46Mから-34.91%の減少でした。 利益は13.87Mで、-85.13%の減少でした。

財務諸表

決算サプライズ

Mesabi TrustはApr 10, 2013に四半期決算を発表しました：
  • 売上高は $2.08M で、予想を下回りました $0, うち -52.23% の前年比減少.
  • EPSは 0.36 で、予想を下回りました -0.06, うち -25.00% の前年比減少.
    news image

    4か月前 · Simply Wall St.

    Assessing Cleveland-Cliffs (CLF) Valuation After Mesabi Trust Distribution Cut Highlights Operational Uncertainty

    Mesabi Trust’s decision to cut its distribution, after receiving lower royalty payments from Cleveland-Cliffs (CLF), has drawn fresh attention to uncertainties around the miner’s Northshore iron ore o...

    news image

    4か月前 · Simply Wall St.

    ASX April 2026 Stocks Estimated To Be Trading Below Fair Value

    The Australian stock market is experiencing a period of optimism, with the ASX 200 futures seeing a significant rise as global equities receive a boost from renewed geopolitical negotiations. Amidst t...

    news image

    4か月前 · Simply Wall St.

    Gregory George Adds To Mesoblast Position With Multi-Market Share Purchases

    Mesoblast Limited ( ASX:MSB ) shareholders (or potential shareholders) will be happy to see that insider Gregory George...

    news image

    4か月前 · Simply Wall St.

    Mesoblast (ASX:MSB) Is Down 11.0% After FDA Clears Registrational DMD Trial For Ryoncil - Has The Bull Case Changed?

    Mesoblast recently announced that the US FDA has granted Investigational New Drug clearance to move directly into a registrational clinical trial of Ryoncil in children with Duchenne muscular dystroph...

    news image

    4か月前 · Simply Wall St.

    Is Mesoblast (ASX:MSB) Price Swings Creating A Possible Valuation Opportunity?

    If you are wondering whether Mesoblast at around A$2.02 is still priced attractively or already reflecting high expectations, the valuation story matters more than ever. The share price has seen mixed...

    2ページ中1ページ